Tag: ES-SCLC

Ifinatamab Deruxtecan (previously known as DS-7300a), a B7-H3-directed antibody-drug conjugate being developed by Daiichi Sankyo and Merck & Co. (known as MSD outside of the United States and Canada), could offer a First-in-Class option for patients diagnosed with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy.

GSK and Duality Biologics have entered into an exclusive option agreement for developing and commercializing DB-1324, a potentially best-in-class antibody-drug conjugate (ADC) candidate.